IS5001A - Bakflæðishemlar - Google Patents

Bakflæðishemlar

Info

Publication number: IS5001A
Authority: IS; Iceland
Prior art keywords: reflux inhibitors; reflux; inhibitors
Prior art date: 1996-09-18

Application number

IS5001A

Other languages

English (en)

Other versions

IS2329B (is

Inventor

L.R. Andrews Paul

Lehmann Anders

Original Assignee

Astra Aktiebolag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-18

Filing date

1999-03-15

Publication date

1999-03-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20403936&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS5001(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-03-15 Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag

1999-03-15 Publication of IS5001A publication Critical patent/IS5001A/is

2008-01-15 Publication of IS2329B publication Critical patent/IS2329B/is

Links

239000003112 inhibitor Substances 0.000 title 1
238000010992 reflux Methods 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/9426—GABA, i.e. gamma-amino-butyrate
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
General Physics & Mathematics (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)
Compounds Of Unknown Constitution (AREA)

IS5001A 1996-09-18 1999-03-15 Bakflæðishemlar IS2329B (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9603408A SE9603408D0 (sv)	1996-09-18	1996-09-18	Medical use
PCT/SE1997/001555 WO1998011885A1 (en)	1996-09-18	1997-09-15	Reflux inhibitors

Publications (2)

Publication Number	Publication Date
IS5001A true IS5001A (is)	1999-03-15
IS2329B IS2329B (is)	2008-01-15

Family

ID=20403936

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IS5001A IS2329B (is)	1996-09-18	1999-03-15	Bakflæðishemlar
IS8623A IS2538B (is)	1996-09-18	2007-03-19	Bakflæðishemlar

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IS8623A IS2538B (is)	1996-09-18	2007-03-19	Bakflæðishemlar

Country Status (34)

Country	Link
US (2)	US6117908A (is)
EP (2)	EP0936906B1 (is)
JP (1)	JP4098832B2 (is)
KR (2)	KR100568659B1 (is)
CN (1)	CN1117560C (is)
AR (1)	AR007747A1 (is)
AT (2)	ATE249212T1 (is)
AU (1)	AU714370B2 (is)
BR (1)	BR9711400A (is)
CA (1)	CA2265615C (is)
CZ (1)	CZ299997B6 (is)
DE (2)	DE69724809T2 (is)
DK (2)	DK1344524T3 (is)
EE (1)	EE03952B1 (is)
ES (2)	ES2206749T3 (is)
HU (1)	HU224968B1 (is)
ID (1)	ID19621A (is)
IL (1)	IL128961A (is)
IS (2)	IS2329B (is)
MY (1)	MY122020A (is)
NO (1)	NO326837B1 (is)
NZ (2)	NZ504244A (is)
PL (1)	PL190028B1 (is)
PT (2)	PT936906E (is)
RU (1)	RU2199316C2 (is)
SA (1)	SA97180522B1 (is)
SE (1)	SE9603408D0 (is)
SI (2)	SI1344524T1 (is)
SK (1)	SK285744B6 (is)
TR (1)	TR199900591T2 (is)
TW (1)	TW548104B (is)
UA (1)	UA61081C2 (is)
WO (1)	WO1998011885A1 (is)
ZA (1)	ZA977969B (is)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100491282B1 (ko)	1996-07-24	2005-05-24	워너-램버트 캄파니 엘엘씨	통증 치료용 이소부틸가바 및 그의 유도체
WO1999008670A1 (en)	1997-08-20	1999-02-25	Guglietta, Antonio	Gaba analogs to prevent and treat gastrointestinal damage
US6127418A (en) *	1997-08-20	2000-10-03	Warner-Lambert Company	GABA analogs to prevent and treat gastrointestinal damage
EP0974351A3 (en) *	1998-04-24	2000-12-13	Jouveinal	Medicament for preventing and treating gastrointestinal damage
US20080207755A1 (en) *	2000-05-31	2008-08-28	Pfizer Inc	Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
US7164034B2 (en) *	1999-06-10	2007-01-16	Pfizer Inc.	Alpha2delta ligands for fibromyalgia and other disorders
SE9904507D0 (sv)	1999-12-09	1999-12-09	Astra Ab	New compounds
US7319095B2 (en) *	1999-12-09	2008-01-15	Astrazeneca Ab	Use of GABAB receptor agonists
SE9904508D0 (sv)	1999-12-09	1999-12-09	Astra Ab	New compounds
TWI256314B (en) *	2000-02-09	2006-06-11	Mitsubishi Pharma Corp	Preventive-therapeutical medicament for gastroesophageal reflux disease
MXPA03011096A (es) *	2001-05-29	2004-12-06	Depomed Dev Ltd	Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
SE0102057D0 (sv) *	2001-06-08	2001-06-08	Astrazeneca Ab	New Salts I
SE0102058D0 (sv) *	2001-06-08	2001-06-08	Astrazeneca Ab	New Salts II
AR033779A1 (es)	2001-06-08	2004-01-07	Astrazeneca Ab	Compuestos utiles en la enfermedad de reflujo
SE0102055D0 (sv) *	2001-06-08	2001-06-08	Astrazeneca Ab	New Compounds
GB0209481D0 (en) *	2002-04-24	2002-06-05	Novartis Ag	Organic compounds
SE0201939D0 (sv) *	2002-06-20	2002-06-20	Astrazeneca Ab	New combination
SE0201943D0 (sv) *	2002-06-20	2002-06-20	Astrazeneca Ab	New use
US7964609B2 (en)	2002-06-20	2011-06-21	Astrazeneca Ab	Use of mGluR5 antagonists for the treatment of gerd
SE0201940D0 (sv) *	2002-06-20	2002-06-20	Astrazeneca Ab	New combination II
GB0226434D0 (en) *	2002-11-13	2002-12-18	Astrazeneca Ab	Combination product
KR20050085636A (ko) *	2002-12-13	2005-08-29	워너-램버트 캄파니 엘엘씨	섬유근육통 및 기타 질환의 치료를 위한 프레가발린 유도체
KR101140559B1 (ko) *	2003-08-20	2012-07-05	제노포트 인코포레이티드	아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
EP2354120A1 (en)	2003-08-20	2011-08-10	XenoPort, Inc.	Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
ATE546427T1 (de) *	2003-08-20	2012-03-15	Xenoport Inc	Acyloxyalkylcarbamat-prodrugs, syntheseverfahren und anwendung
AU2004272302A1 (en) *	2003-09-12	2005-03-24	Janssen Pharmaceutica N.V.	Chimeric GABAb receptor
WO2005037784A2 (en) *	2003-10-14	2005-04-28	Xenoport, Inc.	Crystalline form of gamma-aminobutyric acid analog
GB0327186D0 (en) *	2003-11-21	2003-12-24	Novartis Ag	Organic compounds
US20050220863A1 (en) *	2004-04-02	2005-10-06	Chien-Hsuan Han	Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
US20050226927A1 (en) *	2004-04-02	2005-10-13	Impax Laboratories, Inc.	Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US20050220873A1 (en) *	2004-04-02	2005-10-06	Chien-Hsuan Han	Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US8007827B2 (en) *	2004-04-02	2011-08-30	Impax Laboratories, Inc.	Pharmaceutical dosage forms having immediate release and/or controlled release properties
SE0401653D0 (sv)	2004-06-24	2004-06-24	Astrazeneca Ab	New compounds
WO2006050472A2 (en) *	2004-11-03	2006-05-11	Xenoport, Inc.	Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
WO2006050471A2 (en) *	2004-11-03	2006-05-11	Xenoport, Inc.	Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
WO2006071186A1 (en) *	2004-12-27	2006-07-06	Astrazeneca Ab	Use of gabab receptor agonists
BRPI0620345A2 (pt) *	2005-12-23	2017-11-21	Astrazeneca Ab	composto, composição farmacêutica, uso de um composto, e, métodod para o tratamento de uma doença
JP2009521427A (ja) *	2005-12-23	2009-06-04	アストラゼネカ・アクチエボラーグ	胃食道逆流症及び過敏性腸症候群の治療のためのピラゾール
EP1968946A4 (en) *	2005-12-23	2010-05-05	Astrazeneca Ab	IMIDAZOLE AS MODULATORS OF THE GABA B RECEPTOR
BRPI0620464A2 (pt) *	2005-12-23	2011-11-16	Astrazeneca Ab	composto, composição farmacêutica, uso de um composto, e, método para o tratamento de uma doença
US7745474B2 (en)	2005-12-23	2010-06-29	Astrazeneca Ab	Imidazole derivatives for the treatment of gastrointestinal disorders
WO2008033572A1 (en) *	2006-09-15	2008-03-20	Xenoport, Inc.	Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
NZ598728A (en) *	2006-12-22	2013-09-27	Ironwood Pharmaceuticals Inc	Compositions comprising bile acid sequestrants for treating esophageal disorders
WO2008086492A1 (en) *	2007-01-11	2008-07-17	Xenoport, Inc.	Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
KR20100015648A (ko) *	2007-04-18	2010-02-12	아스트라제네카 아베	양성 알로스테릭 ｇａｂａｂ 수용체 조절제 효과를 갖는 크산틴 화합물
TW200908957A (en) *	2007-06-15	2009-03-01	Xenoport Inc	Use of prodrugs of GABA analogs, antispasticity agents, and prodrugs of GABAB receptor agonists for treating spasticity
JP2010534239A (ja) *	2007-07-25	2010-11-04	アストラゼネカ・アクチエボラーグ	Ｎｅｒｄの治療のための（３−アミノ−２−フルオロプロピル）ホスフィン酸の使用
TW200936123A (en) *	2007-11-06	2009-09-01	Xenoport Inc	Use of prodrugs of GABAb agonists for treating neuropathic and musculoskeletal pain
US7872046B2 (en) *	2008-01-25	2011-01-18	Xenoport, Inc.	Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
WO2009094577A2 (en)	2008-01-25	2009-07-30	Xenoport, Inc.	Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
JP5563483B2 (ja) *	2008-01-25	2014-07-30	ゼノポート，インコーポレイティド	アシロキシアルキルカルバメートプロドラッグの合成に使用されるアシロキシアルキルチオカーボネートの鏡像異性的な分解
US20100137442A2 (en) *	2008-02-01	2010-06-03	Xenoport, Inc.	Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
US8993639B2 (en) *	2008-03-20	2015-03-31	Burt Shulman	Compound and method for treatment of gastroesophageal reflux
WO2010017498A1 (en)	2008-08-07	2010-02-11	Xenoport, Inc.	Methods of synthesizing n-hydroxysuccinimidyl carbonates
US8299291B2 (en) *	2008-08-07	2012-10-30	Xenoport, Inc.	Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
CA2753057C (en) *	2009-03-03	2018-09-11	Xenoport, Inc.	Sustained release oral dosage forms of an r-baclofen prodrug
WO2010120370A2 (en) *	2009-04-17	2010-10-21	Xenoport, Inc.	Gamma-amino-butyric acid derivatives as gabab receptor ligands
WO2011113904A1 (en)	2010-03-17	2011-09-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
WO2013023155A1 (en)	2011-08-11	2013-02-14	Xenoport, Inc.	Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use
EP2854774A4 (en)	2012-06-01	2015-11-18	Lynn Health Science Inst Inc	METHODS OF TREATING INSOMNIA
US12161695B2 (en) *	2018-02-22	2024-12-10	Diamyd Medical Ab	GABA A receptor agonists for treatment of disorders influenced by dysfunction BETA cells
TW202412754A (zh) *	2022-06-07	2024-04-01	瑞士商意梭凱普公司	應用於食道黏膜的包含逆流抑制劑的藥物傳遞系統

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU594424B2 (en) *	1986-01-03	1990-03-08	University Of Melbourne, The	Gastro-oesophageal reflux composition
NO882881L (no) *	1988-06-29	1990-01-02	Trond Nilsen	Anordning for lengdekorrugering av metallplater.
GB8820266D0 (en) *	1988-08-26	1988-09-28	Smith Kline French Lab	Compounds
AU5106790A (en) *	1989-02-03	1990-09-05	Cambridge Neuroscience Research, Inc.	Method of screening and classifying compounds
GB9117716D0 (en) *	1991-08-16	1991-10-02	Lynxvale Ltd	Gaba derivatives and their therapeutic application
EP0713698B1 (en) *	1992-01-22	2002-04-03	Glaxo Group Limited	Medical use of atypical beta-adrenoceptor agonists
GB9408064D0 (en) *	1994-04-22	1994-06-15	Merck Sharp & Dohme	Nucleic acids
US5491134A (en) *	1994-09-16	1996-02-13	Bristol-Myers Squibb Company	Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5656730A (en) *	1995-04-07	1997-08-12	Enzon, Inc.	Stabilized monomeric protein compositions

1996
- 1996-09-18 SE SE9603408A patent/SE9603408D0/xx unknown
1997
- 1997-09-04 ZA ZA9707969A patent/ZA977969B/xx unknown
- 1997-09-04 AR ARP970104051A patent/AR007747A1/es unknown
- 1997-09-12 TW TW086113275A patent/TW548104B/zh not_active IP Right Cessation
- 1997-09-12 ID IDP973172A patent/ID19621A/id unknown
- 1997-09-15 RU RU99107969/14A patent/RU2199316C2/ru not_active IP Right Cessation
- 1997-09-15 SI SI9730749T patent/SI1344524T1/sl unknown
- 1997-09-15 UA UA99031298A patent/UA61081C2/uk unknown
- 1997-09-15 JP JP51458198A patent/JP4098832B2/ja not_active Expired - Fee Related
- 1997-09-15 ES ES97942346T patent/ES2206749T3/es not_active Expired - Lifetime
- 1997-09-15 HU HU9903825A patent/HU224968B1/hu not_active IP Right Cessation
- 1997-09-15 PL PL97332497A patent/PL190028B1/pl not_active IP Right Cessation
- 1997-09-15 DK DK03013667T patent/DK1344524T3/da active
- 1997-09-15 DE DE69724809T patent/DE69724809T2/de not_active Expired - Lifetime
- 1997-09-15 EE EEP199900095A patent/EE03952B1/xx not_active IP Right Cessation
- 1997-09-15 PT PT97942346T patent/PT936906E/pt unknown
- 1997-09-15 ES ES03013667T patent/ES2268227T3/es not_active Expired - Lifetime
- 1997-09-15 EP EP97942346A patent/EP0936906B1/en not_active Expired - Lifetime
- 1997-09-15 CZ CZ0093099A patent/CZ299997B6/cs not_active IP Right Cessation
- 1997-09-15 DE DE69736445T patent/DE69736445T2/de not_active Expired - Lifetime
- 1997-09-15 AT AT97942346T patent/ATE249212T1/de active
- 1997-09-15 CN CN97199600A patent/CN1117560C/zh not_active Expired - Fee Related
- 1997-09-15 KR KR1020057018539A patent/KR100568659B1/ko not_active Expired - Fee Related
- 1997-09-15 EP EP03013667A patent/EP1344524B1/en not_active Expired - Lifetime
- 1997-09-15 BR BR9711400A patent/BR9711400A/pt not_active Application Discontinuation
- 1997-09-15 DK DK97942346T patent/DK0936906T3/da active
- 1997-09-15 SI SI9730594T patent/SI0936906T1/xx unknown
- 1997-09-15 AU AU44064/97A patent/AU714370B2/en not_active Ceased
- 1997-09-15 IL IL12896197A patent/IL128961A/en not_active IP Right Cessation
- 1997-09-15 PT PT03013667T patent/PT1344524E/pt unknown
- 1997-09-15 US US08/952,400 patent/US6117908A/en not_active Expired - Lifetime
- 1997-09-15 AT AT03013667T patent/ATE334700T1/de active
- 1997-09-15 WO PCT/SE1997/001555 patent/WO1998011885A1/en not_active Ceased
- 1997-09-15 NZ NZ504244A patent/NZ504244A/xx not_active IP Right Cessation
- 1997-09-15 NZ NZ334495A patent/NZ334495A/xx not_active IP Right Cessation
- 1997-09-15 CA CA002265615A patent/CA2265615C/en not_active Expired - Fee Related
- 1997-09-15 TR TR1999/00591T patent/TR199900591T2/xx unknown
- 1997-09-15 KR KR1019997002239A patent/KR100553294B1/ko not_active Expired - Fee Related
- 1997-09-15 SK SK305-99A patent/SK285744B6/sk not_active IP Right Cessation
- 1997-09-16 MY MYPI97004296A patent/MY122020A/en unknown
- 1997-10-27 SA SA97180522A patent/SA97180522B1/ar unknown
1999
- 1999-03-15 IS IS5001A patent/IS2329B/is unknown
- 1999-03-17 NO NO19991287A patent/NO326837B1/no not_active IP Right Cessation
2000
- 2000-09-08 US US09/658,242 patent/US6664069B1/en not_active Expired - Fee Related
2007
- 2007-03-19 IS IS8623A patent/IS2538B/is unknown

Also Published As

Publication number	Publication date
IL128961A0 (en)	2000-02-17
HUP9903825A2 (hu)	2001-05-28
ID19621A (id)	1998-07-23
SK30599A3 (en)	2000-01-18
IS2329B (is)	2008-01-15
NZ334495A (en)	2000-09-29
EP1344524B1 (en)	2006-08-02
BR9711400A (pt)	1999-08-17
ZA977969B (en)	1998-03-18
EP0936906B1 (en)	2003-09-10
HUP9903825A3 (en)	2001-06-28
IS2538B (is)	2009-09-15
DE69736445T2 (de)	2007-03-15
MY122020A (en)	2006-03-31
CZ93099A3 (cs)	1999-09-15
TR199900591T2 (xx)	1999-07-21
RU2199316C2 (ru)	2003-02-27
HK1022100A1 (en)	2000-07-28
NO326837B1 (no)	2009-02-23
CA2265615C (en)	2007-01-30
SA97180522B1 (ar)	2006-04-04
PT1344524E (pt)	2006-11-30
EE9900095A (et)	1999-10-15
KR20050101237A (ko)	2005-10-20
EP0936906A1 (en)	1999-08-25
US6664069B1 (en)	2003-12-16
EE03952B1 (et)	2003-02-17
PL190028B1 (pl)	2005-10-31
NZ504244A (en)	2000-09-29
AR007747A1 (es)	1999-11-10
PL332497A1 (en)	1999-09-13
AU4406497A (en)	1998-04-14
SI0936906T1 (en)	2004-02-29
PT936906E (pt)	2003-12-31
HU224968B1 (en)	2006-04-28
CN1117560C (zh)	2003-08-13
IS8623A (is)	2007-03-19
SE9603408D0 (sv)	1996-09-18
DE69724809T2 (de)	2004-07-15
JP4098832B2 (ja)	2008-06-11
ES2206749T3 (es)	2004-05-16
ES2268227T3 (es)	2007-03-16
WO1998011885A1 (en)	1998-03-26
ATE334700T1 (de)	2006-08-15
KR100553294B1 (ko)	2006-02-22
NO991287L (no)	1999-03-17
DK0936906T3 (da)	2003-11-24
IL128961A (en)	2004-08-31
SK285744B6 (sk)	2007-07-06
EP1344524A1 (en)	2003-09-17
KR100568659B1 (ko)	2006-04-07
UA61081C2 (uk)	2003-11-17
JP2001501604A (ja)	2001-02-06
DE69736445D1 (de)	2006-09-14
NO991287D0 (no)	1999-03-17
KR20000036185A (ko)	2000-06-26
DE69724809D1 (de)	2003-10-16
CN1237105A (zh)	1999-12-01
SI1344524T1 (sl)	2006-12-31
CZ299997B6 (cs)	2009-01-14
CA2265615A1 (en)	1998-03-26
HK1057004A1 (en)	2004-03-12
AU714370B2 (en)	1999-12-23
US6117908A (en)	2000-09-12
ATE249212T1 (de)	2003-09-15
TW548104B (en)	2003-08-21
DK1344524T3 (da)	2006-10-30

Publication	Publication Date	Title
DK1344524T3 (da)	2006-10-30	Refluksinhibitorer
FI963597A7 (fi)	1996-11-14	Isoprenyylitransferaasi-inhibiittoreita
NO972930D0 (no)	1997-06-23	Fibronectin-adhesjonsinhibitorer
FI972160A0 (fi)	1997-05-21	Matriisimetalloproteaasi-inhibiittorit
ID19198A (id)	1998-06-28	Inhibitor metaloprotease heterosiklik
DK1004669T3 (da)	2007-08-27	Hidtil ukendte differentieringsinhibitor
NO20002121D0 (no)	2000-04-26	Benzotiazol-protein-tyrosin-kinaseinhibitorer
DK1027332T3 (da)	2004-10-04	Hidtil ukendte lactametalloproteaseinhibitorer
ID18416A (id)	1998-04-09	Inhibitor metaloprotease diheterosiklik
DK0958287T3 (da)	2003-01-20	Sulfamidmetalloprotease-inhibitorer
ID18141A (id)	1998-03-05	Inhibitor metaloprotease 1,3-diheterosiklik
LV12150A (lv)	1998-10-20	Farneziltransferazes inhibitori
ID18995A (id)	1998-05-28	Amida-amida inhibitor apo b-sekresi/mtp
ATE268781T1 (de)	2004-06-15	Thrombininhibitoren
NO20003256D0 (no)	2000-06-22	ACE inhibitor-MMP inhibitor kombinasjoner
ID18417A (id)	1998-04-09	Inhibitor ditentat metaloprotease
FI971156L (fi)	1997-03-19	5alfa-reduktaasi-inhibiittoreita
PT948483E (pt)	2002-08-30	Inibidores da farnesil-transferase
ATE252547T1 (de)	2003-11-15	Matrixmetalloproteinaseinhibitoren
DE69733263D1 (de)	2005-06-16	Markierte elastase-inhibitoren
FI964781A7 (fi)	1997-01-29	Uusia elastaasi-inhibiittoreita
ATE282629T1 (de)	2004-12-15	Thrombininhibitoren
DE69720957T2 (de)	2004-01-29	Ace-hemmer
BR9610514A (pt)	1999-03-30	Inibidores cicloantihelmínticos
EP1007548A4 (en)	2002-07-03	THROMBIN INHIBITOR FROM TSE-TSE FLY